RapidAI has secured $75m in Series C funding to enhance the innovation of its clinical decision and workflow support technology.

The company develops artificial intelligence (AI) and technology workflow solutions to address neurovascular, cardiac and vascular diseases.

The Series C round was led by Vista Credit Partners, a subsidiary of Vista Equity Partners and a strategic financing partner specialising in enterprise software, data and technology markets.

Proceeds from the funding round are intended to fuel platform innovation to enhance support for various diseases, as well as go-to-market operations to help expedite growth in new regions and product verticals.

RapidAI CEO Karim Kart said: “RapidAI’s advanced clinical decision support software goes beyond simple triage and notification to provide specific, relevant and contextual data with tremendous accuracy to satisfy these demands.

“Vista Credit Partners’ support and access to their expertise will advance our vision, technological innovation and go-to-market efforts as we further establish our leadership position in clinical AI solutions for life-threatening diseases.”

RapidAI offers a comprehensive portfolio of stroke solutions, including Rapid NCCT Stroke.

Rapid NCCT Stroke is claimed to be the first and only medical device approved by the US Food and Drug Administration (FDA) for identifying suspected intracranial haemorrhage and large vessel occlusion from non-contrast CT imaging.

The company also provides FDA-approved modules for cerebral aneurysm management, as well as the detection and notification of suspected central pulmonary embolism.

RapidAI is also involved in the development of new modules for other disease states.

Vista Credit Partners president David Flannery said: “RapidAI is playing an outsized role in advancing patient care for life-threatening diseases with innovative clinical AI solutions. We look forward to our partnership and helping the company realise its next phase of growth.”